U.S. markets open in 7 hours 10 minutes

ADC Therapeutics SA (ADCT)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
23.18+0.97 (+4.37%)
At close: 4:00PM EDT

ADC Therapeutics SA

Biopole
Route de la Corniche 3B
Epalinges 1066
Switzerland
41 21 653 02 00
http://www.adctherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees208

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher J. MartinCo-Founder, CEO & DirectorN/AN/A1959
Mr. Michael Forer L.L.B.Vice Chairman, Exec. VP & Gen. CounselN/AN/A1966
Ms. Jennifer CreelChief Financial OfficerN/AN/A1971
Mr. Robert A. SchmidtVP, Corp. Controller & Chief Accounting OfficerN/AN/A1977
Amanda HamiltonInvestor Relations OfficerN/AN/AN/A
Ms. Susan RomanusChief Compliance OfficerN/AN/A1966
Dr. Peter Greaney Ph.D.Head of Corp. Devel.N/AN/A1980
Ms. Kimberly PopeSr. VP & Chief HR OfficerN/AN/A1967
Dr. Patrick van BerkelSr. VP of R&DN/AN/A1969
Dr. Jay M. Feingold M.D., Ph.D.Chief Medical Officer, Head of Oncology Clinical Devel. & Sr. VPN/AN/A1957
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Corporate Governance

ADC Therapeutics SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.